Phone: (650) 368 6983
info@airmid.com
Target Portfolio
1. Unmet Needs
2. AIRMID Novel Therapeutic Approach
3. AIRMIDs Therapeutics
4. Excellent Safety Profiles
5. Proof-of-concept AIRMID Technology
October 2006
AIRMID receives Series A
financing from Biotechnology
Value Fund.
more...
Home
|
Autoimmune disease
|
Multiple sclerosis
|
Type 1 diabetes mellitus
|
Kv1.3 Potassium Channel
|
PAP-1
|
ShK
Effector memory T cells
|
Contact
|
Sitemap
Copyrights © 2007, www.airmid.com